ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

Learn more about:
Related Clinical Trial
Safety & Efficacy Study of Epcoritamab in Subjects With R/R Chronic Lymphocytic Leukemia and Richter’s Syndrome ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL Phase 1 Study VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter’s Syndrome; Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS/MPN, and MF Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter’s Transformation Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia Allogeneic Stem Cell Transplant for CLL Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter’s Transformation Registry of the German CLL Study Group Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter’s Syndrome PNT2258 for Treatment of Patients With Richter’s Transformation (Brighton) Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter’s Transformation Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation BLINAtumomab After R-CHOP Debulking Therapy for Patients With Richter Transformation Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter’s Transformation and Leukemias Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Study of Blinatumomab in Richter Transformation Genomic and Proteomic Study of Richter Syndrome (CGPSR) CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter’s Syndrome Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter’s Transformation or Richter’s Syndrome Patients Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter’s Syndrome A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter’s Syndrome Selinexor in Initial or Refractory and/or Relapsed Richter’s Transformation

Brief Title

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia

Official Title

A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

Brief Summary

      This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (Btk)
      inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (CLL)/small
      lymphocytic lymphoma (SLL)

Study Phase

Phase 1/Phase 2

Study Type


Primary Outcome

Determine the Maximum Tolerated Dose


Chronic Lymphocytic Leukemia



Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 30, 2014

Completion Date

July 15, 2026

Primary Completion Date

July 15, 2021

Eligibility Criteria

        Inclusion Criteria:

          1. Men and women ≥ 18 years of age with a confirmed diagnosis of CLL/SLL, which has
             relapsed after, or been refractory to, ≥ 2 previous treatments for CLL/SLL.

          2. Must have measurable CLL/SLL defined as ≥ 1 lymph node ≥ 2 cm as measured in the
             longest diameter.

          3. Active disease meeting ≥ 1 of the following IWCLL 2008 criteria for requiring

               1. Evidence of progressive marrow failure as manifested by the development of, or
                  worsening of, anemia (hemoglobin < 10 g/dL) and/or thrombocytopenia (platelets <

               2. Massive (i.e., ≥ 6 cm below the left costal margin), progressive, or symptomatic

               3. Massive nodes (i.e., ≥ 10 cm in the longest diameter), progressive, or
                  symptomatic lymphadenopathy.

               4. Progressive lymphocytosis with an increase of > 50% over a 2-month period or a
                  lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear
                  regression extrapolation of absolute lymphocyte counts (ALC) obtained at
                  intervals of 2 weeks over an observation period of 2 to 3 months. In subjects
                  with initial blood lymphocyte counts of < 30 X 109/L (30,000/μL), LDT should not
                  be used as a single parameter to define indication for treatment. In addition,
                  factors contributing to lymphocytosis or lymphadenopathy other than CLL (e.g.,
                  infections) should be excluded.

               5. Autoimmune anemia and/or thrombocytopenia that is poorly responsive to standard

               6. Constitutional symptoms documented in the subject's chart with supportive
                  objective measures, as appropriate, defined as ≥ 1 of the following
                  disease-related symptoms or signs:

             i. Unintentional weight loss ≥ 10% within the previous 6 months before Screening.

             ii. Fevers higher than 100.5°F or 38.0°C for 2 or more weeks before Screening without
             evidence of infection.

             iii. Night sweats for > 1 month before Screening without evidence of infection.

          4. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.

          5. Agreement to use highly effective methods of contraception during the study and for 2
             days after the last dose of study drug if sexually active and able to bear or beget
             children (see Section 3.7.9 for list of highly effective methods of contraception).

          6. Willing and able to participate in all required evaluations and procedures in this
             study protocol including swallowing capsules without difficulty.

          7. Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations).

          8. Removed at Amendment 11.

        Inclusion Criteria for Treatment Subgroups

          1. Treatment Naive only: Men and women ≥ 18 years of age with confirmed diagnosis of
             CLL/SLL, who require treatment per National Cancer Institute (NCI) or International
             Working Group guidelines and a) do not want to receive chemoimmunotherapy or b) have
             comorbidities that would preclude chemoimmunotherapy.

          2. Ibrutinib Intolerant only: Men and women ≥ 18 years of age with confirmed diagnosis of
             CLL/SLL who are not tolerating ibrutinib due to ibrutinib-related AEs.

          3. Richter's Syndrome/Prolymphocytic Leukemia Transformation only: Men and women ≥ 18
             years of age and biopsy proven diffuse large B cell lymphoma (DLBCL) Richter's
             transformation or prolymphocytic leukemia transformation.

          4. Ibrutinib R/R only: Men and women ≥ 18 years of age with confirmed diagnosis of
             CLL/SLL whose best response after 2 cycles of ibrutinib therapy was SD or nonresponse
             or who initially responded to ibrutinib therapy and now have signs of clinical

        Exclusion Criteria:

          1. Prior malignancy, except for adequately treated basal cell, squamous cell skin cancer
             or in situ cervical cancer. Subjects with other prior malignancies from which the
             subject has been disease free for ≥ 2 years may be included if approved by the medical

          2. A life-threatening illness, medical condition or organ system dysfunction which, in
             the investigator's opinion, could compromise the subject's safety, interfere with the
             absorption or metabolism of acalabrutinib, or put the study outcomes at undue risk.

          3. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias,
             congestive heart failure, or myocardial infarction within 6 months of screening, or
             any Class 3 or 4 cardiac disease as defined by the New York Heart Association
             Functional Classification, or left ventricular ejection fraction (LVEF) ≤ 40%.

          4. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or
             resection of the stomach or small bowel, symptomatic inflammatory bowel disease,
             partial or complete bowel obstruction, or gastric restrictions and bariatric surgery,
             such as gastric bypass.

          5. Any immunotherapy within 4 weeks of first dose of study drug.

          6. For subjects with recent chemotherapy or experimental therapy the first dose of study
             drug must occur after 5 times the half-life of the agent(s).

          7. Relapsed after, or refractory to, prior BTK inhibitor therapy (Note: Does not apply to
             Ibrutinib R/R or Richter's Syndrome Group).

          8. Any history of Richter's transformation (Note: Does not apply to Richter's Syndrome

        10. Central nervous system (CNS) involvement by lymphoma. 11. Grade ≥ 2 toxicity (other
        than alopecia) continuing from prior anticancer therapy including radiation.

        12. Known history of human immunodeficiency virus (HIV) or serologic status indicating
        active hepatitis C virus (HCV) or hepatitis B virus (HBV) infection or any uncontrolled
        active systemic infection. Subjects with hepatitis B core antibody positive who are surface
        antigen negative or who are hepatitis C antibody positive will need to have a negative
        polymerase chain reaction (PCR) result before enrollment. Those who are hepatitis B surface
        antigen positive or hepatitis B PCR positive and those who are hepatitis C PCR positive
        will be excluded.

        13. Uncontrolled AIHA or ITP defined as declining hemoglobin or platelet count secondary to
        autoimmune destruction within the screening period or requirement for high doses of
        steroids (> 20 mg daily of prednisone daily or equivalent).

        14. History of stroke or intracranial hemorrhage within 6 months prior to the first dose of
        study drug.

        15. Requires treatment with proton-pump inhibitors (e.g., omeprazole, esomeprazole,
        lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).

        16. Requires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g.,
        phenprocoumon) within 7 days of first dose of study drug.

        17. Major surgery within 4 weeks before first dose of study drug. 18. ANC < 0.75 x 109/L or
        platelet count < 50 x 109/L unless there is bone marrow involvement.

        19. Total bilirubin > 1.5 x ULN (total bilirubin ≤ 2.5 x ULN allowed in subjects with
        autoimmune hemolytic anemia that is otherwise controlled); and aspartate aminotransferase
        (AST) or alanine aminotransferase (ALT) > 3.0 x ULN unless disease related.

        20. Serum amylase > 1.5 x ULN or serum lipase > 1.5 x ULN. 21. Significant screening ECG
        abnormalities including, 2nd degree AV block type II, 3rd degree block, Grade 2 or higher
        bradycardia, or QTc ≥ 480 ms.

        22. Cardiac troponin I levels above the limit of normal as specified by the manufacturer.

        23. Breast feeding or pregnant. 24. History of bleeding diathesis (e.g., hemophilia, von
        Willebrand disease). 25. Concurrent participation in another therapeutic clinical trial.
        26. Estimated creatinine clearance of < 30 mL/min, calculated using the formula of
        Cockcroft and Gault [(140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if

        27. Presence of a gastrointestinal ulcer diagnosed by endoscopy within 3 months before




18 Years - 130 Years

Accepts Healthy Volunteers



Acerta Clinical Trials, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

Acerta Pharma BV

Study Sponsor

Acerta Clinical Trials, Study Director, 1-888-292-9613 [email protected]

Verification Date

April 2022